 The study protocol 100 patients with heart failure NYHA New York Heart Association II-IV stable or exacerbation aligned cardiopulmonary at the time of enrollment, with a fixed-dose loop diuretics treated with optimal medical therapy as clinically indicated for use loop diuretics. Patients will be randomized to treatment with furosemide and torasemide randomization 1 : 1. After randomization, furosemide will continue in its current fixed-dose or will be replaced by equipotential dose of torasemide 4:1. The minimal follow-up of patients in the study will be at least six months. 